all most interesting. From my own perspective I've decided to put this one in my bottom drawer and take it out for a look at the end of this year. Drug stocks invariably promise much but the downside is usually that it takes a very long time to bring to fulfil that early promise. I have no illusions here but intend to hold long. Gla
LATEST research report.
Published today-looks great. http://www.futuramedical.com/content/investors/research.asp
Info from web results presentation
Info from presentation http://www.futuramedical.co.uk/archive/2014ar.pdf Weildy-instead of going on a bit you should have listened to results webcast-lots discussed and the future looks much more exciting than the written words.
I really cannot see anything to get excited about. More jam tomorrow and missed dates. I have held these for over 5 years now and am getting a bit weary of Mr Barder's smoke and mirrors. Great products, stifled by poor management. The two year shelf life problem is exactly that - a problem and it is increasingly apparent that they will not achieve it. The only bright spot in the report is that they have at last got their asses into gear to progress the TPR products - but I'm not holding my breath. Sorry if this puts a dampener on other investors enthusiasm.
Was excellent. On Sales there was a question - so sales in 2.5 months is 40kEuro - on-line only. On-line is only 6-10% of total market. They have 17% of in-line sales already in NL and 10% in BE. It will be going into retail after the update the wholesellers on shelf life info - so 2H 2015. Quick fag packer menas that if they can also create 17% of all retail sales - which I agree is a tall order then annual sales could be in teh order of 2.4mEuro just for NL and BE. The big news really is "lot of interest from big pharma" this is on the topical. The study is enough to apply for approval in some markets. The blow the lights our stuff is teh comparator against ORAL dislofenac. If they show non-infieriorty and plamsa levale of less that 10% or oral it is in effect better and safer than oral in a chronis settting. This is not enough for approval but they would then need a patinet study. If this happens it will blow the lights out. Study results in July will be a major turning point Also erectile gell will launch in UK in 2H 2015 as a "special" in the UK. Study in 140 patients starts today. Shelf life is being worked on - they are confiendet it will improve but they cant gauantee 2 years.
To be honest I'm disappointed. Revenues down significantly on last year and losses up. Shelf life work of CSD 500 was supposed to have been completed at end of last year. No revenue or meaningful sales info for BD. Price however seems to be holding but I've decided to sell up. May come back in later.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.